Latest Fluidigm Corp (FLDM) Headlines
Fluidigm to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 8:01AM CST
Fluidigm Corporation (NASDAQ:FLDM) today announced that it will present at the Cowen and Company 34th Annual Health Care Conference in Boston, on Tuesday, March 4, 2014, at 8:40 a.m. (EST).
Prenatal Testing Market in the US 2014-2018: Perkinelmer Inc. Expands its Screening Test Offerings, Introducing the First Early Onset Preeclampsia Screening Test in the US in 2013
M2 - Tue Feb 25, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/x2lvh8/prenatal_testing) has announced the addition of the "Prenatal Testing Market in the US 2014-2018" report to their offering. The analysts forecast the Prenatal Testing market in the US to grow at a CAGR of 5.43 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of fetal health-related abnormalities. The Prenatal Testing market in the US has also been witnessing the significant increase in the launch of new tests. However, the falling fertility rates in the US could pose a challenge to the growth of this market. Key vendors dominating this space are PerkinElmer Inc., Quest Diagnostics Inc., Sequenom Inc., and Verinata Health Inc. Other vendors mentioned in the report are ANGLE plc, Ariosa Diagnostics Inc., BGI Health, CellScape Corp., Fluidigm Corp., Ikonisys Inc., Kellbenx Inc., Natera Inc., Ravgen Inc., and Trovagene Inc. Commenting on the report, an analyst from the team said: The Prenatal Testing market in the US is experiencing a significant increase in the number of new tests being launched in the market. For instance, Sequenom launched Laboratoire Cerba's non-invasive prenatal test in San Diego, California, and Saint-Ouen-L'Aumone, France, in December 2013 and enhanced the sequencing series for its MaterniT21 PLUS laboratory-developed test in October 2013. Moreover, PerkinElmer Inc. expanded its prenatal screening test offerings, introducing the first early onset preeclampsia screening test in the US in August 2013. This trend will have a positive impact on the growth of the market. According to the report, one of the major factors driving the market is the increase in the incidence of fetal abnormalities such as Down syndrome, Edwards syndrome, neural tube defects, and genetic defects and disorders such as sickle cell anemia, thalassemia, spina bifida, Tay Sachs disease, cystic fibrosis, muscular dystrophy, cleft palate and fragile X syndrome. For more information visit http://www.researchandmarkets.com/research/x2...al_testing About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Fluidigm Completes Acquisition of DVS Sciences
Business Wire - Thu Feb 13, 3:30PM CST
Fluidigm Corp. (NASDAQ: FLDM) today announced it has completed its acquisition of DVS Sciences, Inc. With the closing of the acquisition, Fluidigm adds a high-parameter single-cell protein analysis platform to its industry-leading single-cell genomics platforms to create a comprehensive portfolio of advanced technologies serving the rapidly growing single-cell genomics and proteomics markets.
Research and Markets: Myo-inositol (CAS 87-89-8) Market Research Report 2013
Business Wire - Wed Feb 12, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/zh7psm/myoinositol_cas) has announced the addition of the "Myo-inositol (CAS 87-89-8) Market Research Report 2013" report to their offering.
Fluidigm Corporation (FLDM) Crumbles: Stock Falls by 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 7:30AM CST
The shares of Fluidigm Corporation fell over 6% on the day.This reverses the most recent uptrend for the company, as the stock is now up almost 8% since Jan 29.This scientific instruments company has seen a flat track record when it comes to current year estimate revisions.
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 07, 5:24PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Fluidigm Reports Strong Revenue for Q4 and the Full Year 2013
Business Wire - Thu Feb 06, 3:00PM CST
Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the fourth quarter and full year ended December 31, 2013.
Insider Trading Alert - CMA, FLDM, CNQR, MFRM And AWAY Traded By Insiders
at The Street - Thu Feb 06, 9:30AM CST
Stocks with insider trader activity include CMA, FLDM, CNQR, MFRM and AWAY
Fluidigm to Announce Q4/Full Year 2013 Financial Results and Host Conference Call for Investors
Business Wire - Fri Jan 31, 5:30PM CST
Fluidigm Corporation (NASDAQ:FLDM) will report its fourth quarter and 2013 full year financial results on February 6, 2014, after close of market.
Fluidigm Announces Pricing of $175 Million Convertible Senior Notes Offering
Business Wire - Thu Jan 30, 7:00AM CST
Fluidigm Corporation (NASDAQ:FLDM), a supplier of microfluidic systems for growth markets in the life science and agricultural biotechnology industries, today announced the pricing of its offering of $175 million aggregate principal amount of its 2.75% convertible senior notes due 2034 (the "notes") in an underwritten public offering. Fluidigm has granted the underwriter of the notes a 30-day option to purchase up to an additional $26.25 million aggregate principal amount of the notes to cover over-allotments, if any. The offering is expected to close on or around February 4, 2014, subject to satisfaction of customary closing conditions.
Fluidigm Announces Proposed $175 Million Convertible Senior Notes Offering
Business Wire - Wed Jan 29, 7:31AM CST
Fluidigm Corporation (NASDAQ: FLDM), a supplier of microfluidic systems for growth markets in the life science and agricultural biotechnology industries, today announced that it intends to offer, subject to market conditions and other factors, $175 million aggregate principal amount of its convertible senior notes due 2034 (the "notes") in an underwritten public offering. Fluidigm also expects to grant the underwriter of the notes a 30-day option to purchase up to an additional $26.25 million aggregate principal amount of the notes to cover over-allotments, if any.
Fluidigm and DVS Sciences Announce Agreement for Fluidigm to Acquire DVS Sciences - Creating a Single-Cell Technology Powerhouse
Business Wire - Wed Jan 29, 6:00AM CST
Continuing its strategy of delivering disruptive single-cell analysis capabilities to life science researchers around the world, Fluidigm Corporation (NASDAQ:FLDM) has entered into a definitive agreement to acquire DVS Sciences, Inc. (DVS) to create a single-cell technology powerhouse. Combined with DVS, Fluidigm will be able to offer a comprehensive portfolio of advanced technologies serving the rapidly growing single-cell genomics and proteomics markets.
Commit To Purchase Fluidigm At $35, Earn 19.8% Annualized Using Options
at The Street - Thu Jan 16, 10:49AM CST
Investors eyeing a purchase of Fluidigm stock, but cautious about paying the going market price of $41.57/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
Fluidigm Jumps on Guidance Boost - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 15, 4:41PM CST
Shares of Fluidigm Corporation Jumped 7.2% as it released a solid fiscal 2014 revenue guidance.
Global DNA Sequencing Equipment and Services Market 2012-2016
M2 - Tue Jan 14, 8:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvdznf/global_dna) has announced the addition of the "Global DNA Sequencing Equipment and Services Market 2012-2016" report to their offering. One of the main trends witnessed in the Global DNA Sequencing Equipment and Services market is increase in number of DNA sequencing projects. The Global DNA Sequencing Equipment and Services market has recently witnessed a significant increase in the number of projects funded by the leading vendors. For instance, Illumina and Partners HealthCare System Inc. announced a strategic alliance in September 2012, in order to offer infrastructure and networking tools for the interpretation and reporting process on genetic sequencing data. Moreover, Hoffmann-La Roche Ltd. and SoftGenetics LLC signed a co-promotion agreement in May 2012 for a new sequencing software tool. Roche and PerkinElmer Inc. announced a new supply agreement in May 2011 for the distribution of the NimbleGen CGX microarray workflow. In addition, Pacific Biosciences announced collaboration in July 2012, with Imec, a Belgium-based nanoelectronics research center focusing on the improvement of innovative microchips for multiplexed single-molecule genetic analysis. Key questions answered in this report: - What will the market size be in 2016 and what will be the growth rate? - What are key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Accelrys - Agilent Technologies - BGI - Biotique Systems - DNA Electronics - DNASTAR - DNAVision - DNAnexus - Danaher Corp. - Eurofins Scientific - Fluidigm Corp. - Foundation Medicine - Good Start Genetics - HelicosBioSciences - IBM Corp. - Illumina - IntegenX - Knome - Laboratory Corp. of America Holdings - Life Technologies - Macrogen - Oxford Nanopore Technologies - PerkinElmer - QIAGEN - RainDance Technologies - Sequenom - Siemens Healthcare - Source BioScience - TheragenEtex For more information visit http://www.researchandmarkets.com/research/wvdznf/global_dna
Fluidigm Announces Preliminary Fourth Quarter 2013 Revenue and Issues 2014 Revenue Guidance
Business Wire - Tue Jan 14, 8:00AM CST
Fluidigm Corporation (NASDAQ:FLDM) today announced total revenue for the fourth quarter of 2013 is expected to be approximately $21 million based on preliminary, unaudited financial data. Instrument revenue is expected to be approximately $12 million and consumables revenue is expected to be approximately $8.5 million. Fluidigm's instrument installed base increased to approximately 920 units at the end of Q4 2013.
Fluidigm to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Business Wire - Wed Jan 08, 8:00AM CST
Fluidigm Corporation (NASDAQ:FLDM) today announced that President and Chief Executive Officer Gajus Worthington will present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, on Thursday, January 16, 2014, at 8:30 a.m. (PST).
Growing Research Focus on Single Cell Biology Drives the Market for Single Cell Omics, According to a New Trend Report Published by Global Industry Analysts, Inc.
PRWeb - Fri Jan 03, 8:22AM CST
Follow us on LinkedIn - Single Cell Omics, a cutting edge technology, mainly integrates advanced technology with biology for a variety of single cell applications. Single Cell Omics, a strong diagnostic and clinical research tool, enables researchers in comprehending cellular variations during cell proliferation; investigating cycle-dependent effects in single cells; and detecting cellular subpopulations as well as differentiation states. Developments targeted at improving sensitivity and throughput of single cell omics technologies are additionally expected to benefit the market.
Nature Selects "Single-Cell Sequencing" as the 2013 Method of the Year
Business Wire - Tue Dec 31, 8:29AM CST
Nature Publishing Group has selected single-cell sequencing as its Method of the Year for 2013 (www.nature.com/nmeth/index.html). The publication, in explaining its choice, noted that "methods to sequence the DNA and RNA of single cells are poised to transform many areas of biology and medicine." The publication continued: "Single-cell genome and transcriptome sequencing methods are generating a fresh wave of biological insights into development, cancer and neuroscience."
Fluidigm to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 8:01AM CST
Fluidigm Corporation (NASDAQ:FLDM) today announced that it will present at the Cowen and Company 34th Annual Health Care Conference in Boston, on Tuesday, March 4, 2014, at 8:40 a.m. (EST).
Prenatal Testing Market in the US 2014-2018: Perkinelmer Inc. Expands its Screening Test Offerings, Introducing the First Early Onset Preeclampsia Screening Test in the US in 2013
M2 - Tue Feb 25, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/x2lvh8/prenatal_testing) has announced the addition of the "Prenatal Testing Market in the US 2014-2018" report to their offering. The analysts forecast the Prenatal Testing market in the US to grow at a CAGR of 5.43 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of fetal health-related abnormalities. The Prenatal Testing market in the US has also been witnessing the significant increase in the launch of new tests. However, the falling fertility rates in the US could pose a challenge to the growth of this market. Key vendors dominating this space are PerkinElmer Inc., Quest Diagnostics Inc., Sequenom Inc., and Verinata Health Inc. Other vendors mentioned in the report are ANGLE plc, Ariosa Diagnostics Inc., BGI Health, CellScape Corp., Fluidigm Corp., Ikonisys Inc., Kellbenx Inc., Natera Inc., Ravgen Inc., and Trovagene Inc. Commenting on the report, an analyst from the team said: The Prenatal Testing market in the US is experiencing a significant increase in the number of new tests being launched in the market. For instance, Sequenom launched Laboratoire Cerba's non-invasive prenatal test in San Diego, California, and Saint-Ouen-L'Aumone, France, in December 2013 and enhanced the sequencing series for its MaterniT21 PLUS laboratory-developed test in October 2013. Moreover, PerkinElmer Inc. expanded its prenatal screening test offerings, introducing the first early onset preeclampsia screening test in the US in August 2013. This trend will have a positive impact on the growth of the market. According to the report, one of the major factors driving the market is the increase in the incidence of fetal abnormalities such as Down syndrome, Edwards syndrome, neural tube defects, and genetic defects and disorders such as sickle cell anemia, thalassemia, spina bifida, Tay Sachs disease, cystic fibrosis, muscular dystrophy, cleft palate and fragile X syndrome. For more information visit http://www.researchandmarkets.com/research/x2...al_testing About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Fluidigm Completes Acquisition of DVS Sciences
Business Wire - Thu Feb 13, 3:30PM CST
Fluidigm Corp. (NASDAQ: FLDM) today announced it has completed its acquisition of DVS Sciences, Inc. With the closing of the acquisition, Fluidigm adds a high-parameter single-cell protein analysis platform to its industry-leading single-cell genomics platforms to create a comprehensive portfolio of advanced technologies serving the rapidly growing single-cell genomics and proteomics markets.
Research and Markets: Myo-inositol (CAS 87-89-8) Market Research Report 2013
Business Wire - Wed Feb 12, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/zh7psm/myoinositol_cas) has announced the addition of the "Myo-inositol (CAS 87-89-8) Market Research Report 2013" report to their offering.
Fluidigm Corporation (FLDM) Crumbles: Stock Falls by 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 7:30AM CST
The shares of Fluidigm Corporation fell over 6% on the day.This reverses the most recent uptrend for the company, as the stock is now up almost 8% since Jan 29.This scientific instruments company has seen a flat track record when it comes to current year estimate revisions.
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 07, 5:24PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Fluidigm Reports Strong Revenue for Q4 and the Full Year 2013
Business Wire - Thu Feb 06, 3:00PM CST
Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the fourth quarter and full year ended December 31, 2013.
Insider Trading Alert - CMA, FLDM, CNQR, MFRM And AWAY Traded By Insiders
at The Street - Thu Feb 06, 9:30AM CST
Stocks with insider trader activity include CMA, FLDM, CNQR, MFRM and AWAY
Fluidigm to Announce Q4/Full Year 2013 Financial Results and Host Conference Call for Investors
Business Wire - Fri Jan 31, 5:30PM CST
Fluidigm Corporation (NASDAQ:FLDM) will report its fourth quarter and 2013 full year financial results on February 6, 2014, after close of market.
Fluidigm Announces Pricing of $175 Million Convertible Senior Notes Offering
Business Wire - Thu Jan 30, 7:00AM CST
Fluidigm Corporation (NASDAQ:FLDM), a supplier of microfluidic systems for growth markets in the life science and agricultural biotechnology industries, today announced the pricing of its offering of $175 million aggregate principal amount of its 2.75% convertible senior notes due 2034 (the "notes") in an underwritten public offering. Fluidigm has granted the underwriter of the notes a 30-day option to purchase up to an additional $26.25 million aggregate principal amount of the notes to cover over-allotments, if any. The offering is expected to close on or around February 4, 2014, subject to satisfaction of customary closing conditions.
Fluidigm Announces Proposed $175 Million Convertible Senior Notes Offering
Business Wire - Wed Jan 29, 7:31AM CST
Fluidigm Corporation (NASDAQ: FLDM), a supplier of microfluidic systems for growth markets in the life science and agricultural biotechnology industries, today announced that it intends to offer, subject to market conditions and other factors, $175 million aggregate principal amount of its convertible senior notes due 2034 (the "notes") in an underwritten public offering. Fluidigm also expects to grant the underwriter of the notes a 30-day option to purchase up to an additional $26.25 million aggregate principal amount of the notes to cover over-allotments, if any.
Fluidigm and DVS Sciences Announce Agreement for Fluidigm to Acquire DVS Sciences - Creating a Single-Cell Technology Powerhouse
Business Wire - Wed Jan 29, 6:00AM CST
Continuing its strategy of delivering disruptive single-cell analysis capabilities to life science researchers around the world, Fluidigm Corporation (NASDAQ:FLDM) has entered into a definitive agreement to acquire DVS Sciences, Inc. (DVS) to create a single-cell technology powerhouse. Combined with DVS, Fluidigm will be able to offer a comprehensive portfolio of advanced technologies serving the rapidly growing single-cell genomics and proteomics markets.
Commit To Purchase Fluidigm At $35, Earn 19.8% Annualized Using Options
at The Street - Thu Jan 16, 10:49AM CST
Investors eyeing a purchase of Fluidigm stock, but cautious about paying the going market price of $41.57/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
Fluidigm Jumps on Guidance Boost - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 15, 4:41PM CST
Shares of Fluidigm Corporation Jumped 7.2% as it released a solid fiscal 2014 revenue guidance.
Global DNA Sequencing Equipment and Services Market 2012-2016
M2 - Tue Jan 14, 8:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvdznf/global_dna) has announced the addition of the "Global DNA Sequencing Equipment and Services Market 2012-2016" report to their offering. One of the main trends witnessed in the Global DNA Sequencing Equipment and Services market is increase in number of DNA sequencing projects. The Global DNA Sequencing Equipment and Services market has recently witnessed a significant increase in the number of projects funded by the leading vendors. For instance, Illumina and Partners HealthCare System Inc. announced a strategic alliance in September 2012, in order to offer infrastructure and networking tools for the interpretation and reporting process on genetic sequencing data. Moreover, Hoffmann-La Roche Ltd. and SoftGenetics LLC signed a co-promotion agreement in May 2012 for a new sequencing software tool. Roche and PerkinElmer Inc. announced a new supply agreement in May 2011 for the distribution of the NimbleGen CGX microarray workflow. In addition, Pacific Biosciences announced collaboration in July 2012, with Imec, a Belgium-based nanoelectronics research center focusing on the improvement of innovative microchips for multiplexed single-molecule genetic analysis. Key questions answered in this report: - What will the market size be in 2016 and what will be the growth rate? - What are key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Accelrys - Agilent Technologies - BGI - Biotique Systems - DNA Electronics - DNASTAR - DNAVision - DNAnexus - Danaher Corp. - Eurofins Scientific - Fluidigm Corp. - Foundation Medicine - Good Start Genetics - HelicosBioSciences - IBM Corp. - Illumina - IntegenX - Knome - Laboratory Corp. of America Holdings - Life Technologies - Macrogen - Oxford Nanopore Technologies - PerkinElmer - QIAGEN - RainDance Technologies - Sequenom - Siemens Healthcare - Source BioScience - TheragenEtex For more information visit http://www.researchandmarkets.com/research/wvdznf/global_dna
Fluidigm Announces Preliminary Fourth Quarter 2013 Revenue and Issues 2014 Revenue Guidance
Business Wire - Tue Jan 14, 8:00AM CST
Fluidigm Corporation (NASDAQ:FLDM) today announced total revenue for the fourth quarter of 2013 is expected to be approximately $21 million based on preliminary, unaudited financial data. Instrument revenue is expected to be approximately $12 million and consumables revenue is expected to be approximately $8.5 million. Fluidigm's instrument installed base increased to approximately 920 units at the end of Q4 2013.
Fluidigm to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Business Wire - Wed Jan 08, 8:00AM CST
Fluidigm Corporation (NASDAQ:FLDM) today announced that President and Chief Executive Officer Gajus Worthington will present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, on Thursday, January 16, 2014, at 8:30 a.m. (PST).
Growing Research Focus on Single Cell Biology Drives the Market for Single Cell Omics, According to a New Trend Report Published by Global Industry Analysts, Inc.
PRWeb - Fri Jan 03, 8:22AM CST
Follow us on LinkedIn - Single Cell Omics, a cutting edge technology, mainly integrates advanced technology with biology for a variety of single cell applications. Single Cell Omics, a strong diagnostic and clinical research tool, enables researchers in comprehending cellular variations during cell proliferation; investigating cycle-dependent effects in single cells; and detecting cellular subpopulations as well as differentiation states. Developments targeted at improving sensitivity and throughput of single cell omics technologies are additionally expected to benefit the market.
Nature Selects "Single-Cell Sequencing" as the 2013 Method of the Year
Business Wire - Tue Dec 31, 8:29AM CST
Nature Publishing Group has selected single-cell sequencing as its Method of the Year for 2013 (www.nature.com/nmeth/index.html). The publication, in explaining its choice, noted that "methods to sequence the DNA and RNA of single cells are poised to transform many areas of biology and medicine." The publication continued: "Single-cell genome and transcriptome sequencing methods are generating a fresh wave of biological insights into development, cancer and neuroscience."
